Spyre Therapeutics Inc
spyre.comWhat Do They Do?
Develops investigational antibody treatments and antibody combinations for people with inflammatory bowel and rheumatic diseases.
10-K for FY2025, filed Feb 19, 2026
Who Are Their Customers?
Immedica was the commercial partner and licensee for pegzilarginase in Europe and several Middle Eastern countries. For future products, Spyre plans to commercialize in the United States and other key markets through its own infrastructure and/or external partnerships.
10-K for FY2025, filed Feb 19, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 4, 2026
−$36.2MView ↗
- ▼ −1% (Loss)
- vs −$36.7M in Q2 FY2025
-
Jun 1, 2026
SPY003 license expanded beyond inflammatory bowel disease
The amended license covers additional uses, with limits on when Spyre can begin human trials outside inflammatory bowel disease.
Sources
8-K, filed Jun 1, 2026
On May 29, 2026, the Company entered into the First Amendment to Amended and Restated License Agreement (the "Amendment"), amending the…View ↗
From rare diseases to immunology
The older report described enzyme therapies for rare metabolic diseases, including homocystinuria and arginase deficiency. The latest describes antibody candidates for inflammatory bowel disease and other immune-mediated diseases.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Feb 19, 2026We are a clinical-stage biotechnology company developing human enzyme therapeutics to benefit people with rare metabolic diseases. Our…View ↗
Pegtarviliase is currently being investigated for the treatment of Classical Homocystinuria. The drug is an investigational PEGylated, or…View ↗
Pegzilarginase is a recombinant human arginase 1 that is engineered to enzymatically degrade the amino acid arginine to reduce elevated…View ↗
Who Do They Compete With?
Competes with AbbVie, Johnson & Johnson, Lilly, Takeda, Pfizer, Bristol Myers Squibb, Merck, Sanofi, Teva, Innovent, Gilead, Palisade Bio, Xencor, Sorriso, Simcere, Boehringer Ingelheim, UCB, Amgen, Roche, and Sobi
10-K for FY2025, filed Feb 19, 2026We expect to face intense competition from other biopharmaceutical companies that are developing agents for the treatment of inflammatory…View ↗
Loading...
